How And-1 helps repair UV-damaged DNA
The role of And-1 in nucleotide excision repair
['FUNDING_R01'] · GEORGE WASHINGTON UNIVERSITY · NIH-11258959
This project looks at how the protein And-1 helps cells fix bulky DNA damage from UV light, which matters for people at risk of skin cancer or with Xeroderma Pigmentosum.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11258959 on ClinicalTrials.gov |
What this research studies
From a patient's point of view, researchers are studying how cells finish the final "patching" step after UV or chemical damage so the DNA is fully restored. They will use lab models (including cell systems and insights from yeast) to compare normal cells and cells lacking And-1 and then measure repair efficiency and UV sensitivity. The team will examine the molecular actions that turn on the DNA gap-filling machinery and how And-1 contributes to chromosome stability. Findings come from laboratory experiments rather than a clinical treatment trial.
Who could benefit from this research
Good fit: People with high UV sensitivity, a personal or family history of skin cancer, or a genetic disorder such as Xeroderma Pigmentosum would be most relevant to this research.
Not a fit: Patients seeking immediate treatment or symptom relief should not expect direct benefit, since the project is laboratory-based mechanistic research rather than a clinical therapy.
Why it matters
Potential benefit: If successful, this work could point to new ways to prevent or treat UV-related skin cancers and help people with DNA repair disorders like Xeroderma Pigmentosum.
How similar studies have performed: Related work in yeast showed the And-1 equivalent affects UV sensitivity, but the specific role of human And-1 in the late, gap-filling step of NER is still largely untested.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, WENGE — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: ZHU, WENGE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers